Targeting minimal residual disease: a path to cure?

被引:118
作者
Luskin, Marlise R. [1 ]
Murakami, Mark A. [1 ]
Manalis, Scott R. [2 ,3 ,4 ]
Weinstock, David M. [1 ,5 ]
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
[2] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA
[3] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA
[4] MIT, Dept Mech Engn, Cambridge, MA 02139 USA
[5] Broad Inst Massachusetts Inst Technol & Harvard U, Cambridge, MA 02142 USA
关键词
ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CELL LUNG-CANCER; CIRCULATING TUMOR-CELLS; SINGLE CELLS; CLINICAL-SIGNIFICANCE; TYROSINE KINASE; FLOW-CYTOMETRY; ADULT PATIENTS; BREAST-CANCER;
D O I
10.1038/nrc.2017.125
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Therapeutics that block kinases, transcriptional modifiers, immune checkpoints and other biological vulnerabilities are transforming cancer treatment. As a result, many patients achieve dramatic responses, including complete radiographical or pathological remission, yet retain minimal residual disease (MRD), which results in relapse. New functional approaches can characterize clonal heterogeneity and predict therapeutic sensitivity of MRD at a single-cell level. Preliminary evidence suggests that iterative detection, profiling and targeting of MRD would meaningfully improve outcomes and may even lead to cure.
引用
收藏
页码:255 / 263
页数:9
相关论文
共 132 条
  • [1] Determining the origin of synchronous multifocal bladder cancer by exome sequencing
    Acar, Omer
    Ozkurt, Ezgi
    Demir, Gulfem
    Sarac, Hilal
    Alkan, Can
    Esen, Tarik
    Somel, Mehmet
    Lack, Nathan A.
    [J]. BMC CANCER, 2015, 15
  • [2] Single cells from human primary colorectal tumors exhibit polyfunctional heterogeneity in secretions of ELR plus CXC chemokines
    Adalsteinsson, Viktor A.
    Tahirova, Narmin
    Tallapragada, Naren
    Yao, Xiaosai
    Campion, Liam
    Angelini, Alessandro
    Douce, Thomas B.
    Huang, Cindy
    Bowman, Brittany
    Williamson, Christina A.
    Kwon, Douglas S.
    Wittrup, K. Dane
    Love, J. Christopher
    [J]. INTEGRATIVE BIOLOGY, 2013, 5 (10) : 1272 - 1281
  • [3] Minimum lesion detectability as a measure of PET system performance
    Adler, Stephen
    Seidel, Jurgen
    Choyke, Peter
    Knopp, Michael V.
    Binzel, Katherine
    Zhang, Jun
    Barker, Craig
    Conant, Shielah
    Maass-Moreno, Roberto
    [J]. EJNMMI PHYSICS, 2017, 4
  • [4] Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
    Albain, K.
    Anderson, S.
    Arriagada, R.
    Barlow, W.
    Bergh, J.
    Bliss, J.
    Buyse, M.
    Cameron, D.
    Carrasco, E.
    Clarke, M.
    Correa, C.
    Coates, A.
    Collins, R.
    Costantino, J.
    Cutter, D.
    Cuzick, J.
    Darby, S.
    Davidson, N.
    Davies, C.
    Davies, K.
    Delmestri, A.
    Di Leo, A.
    Dowsett, M.
    Elphinstone, P.
    Evans, V.
    Ewertz, M.
    Gelber, R.
    Gettins, L.
    Geyer, C.
    Goldhirsch, A.
    Godwin, J.
    Gray, R.
    Gregory, C.
    Hayes, D.
    Hill, C.
    Ingle, J.
    Jakesz, R.
    James, S.
    Kaufmann, M.
    Kerr, A.
    MacKinnon, E.
    McGale, P.
    McHugh, T.
    Norton, L.
    Ohashi, Y.
    Paik, S.
    Pan, H. C.
    Perez, E.
    Peto, R.
    Piccart, M.
    [J]. LANCET, 2012, 379 (9814) : 432 - 444
  • [5] Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
    Andre, Thierry
    Boni, Corrado
    Navarro, Matilde
    Tabernero, Josep
    Hickish, Tamas
    Topham, Clare
    Bonetti, Andrea
    Clingan, Philip
    Bridgewater, John
    Rivera, Fernando
    de Gramont, Aimery
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) : 3109 - 3116
  • [6] Examining the utility of patient-derived xenograft mouse models
    Aparicio, Samuel
    Hidalgo, Manuel
    Kung, Andrew L.
    [J]. NATURE REVIEWS CANCER, 2015, 15 (05) : 311 - 316
  • [7] The aggressive peripheral T-cell lymphomas: 2017
    Armitage, James O.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (07) : 706 - 715
  • [8] Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
    Ascierto, Paolo A.
    McArthur, Grant A.
    Dreno, Brigitte
    Atkinson, Victoria
    Liszkay, Gabrielle
    Di Giacomo, Anna Maria
    Mandala, Mario
    Demidov, Lev
    Stroyakovskiy, Daniil
    Thomas, Luc
    de la Cruz-Merino, Luis
    Dutriaux, Caroline
    Garbe, Claus
    Yan, Yibing
    Wongchenko, Matthew
    Chang, Ilsung
    Hsu, Jessie J.
    Koralek, Daniel O.
    Rooney, Isabelle
    Ribas, Antoni
    Larkin, James
    [J]. LANCET ONCOLOGY, 2016, 17 (09) : 1248 - 1260
  • [9] Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia
    Beldjord, Kheira
    Chevret, Sylvie
    Asnafi, Vahid
    Huguet, Francoise
    Boulland, Marie-Laure
    Leguay, Thibaut
    Thomas, Xavier
    Cayuela, Jean-Michel
    Grardel, Nathalie
    Chalandon, Yves
    Boissel, Nicolas
    Schaefer, Beat
    Delabesse, Eric
    Cave, Helene
    Chevallier, Patrice
    Buzyn, Agnes
    Fest, Thierry
    Reman, Oumedaly
    Vernant, Jean-Paul
    Lheritier, Veronique
    Bene, Marie C.
    Lafage, Marina
    Macintyre, Elizabeth
    Ifrah, Norbert
    Dombret, Herve
    [J]. BLOOD, 2014, 123 (24) : 3739 - 3749
  • [10] Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
    Blanke, Charles D.
    Rankin, Cathryn
    Demetri, George D.
    Ryan, Christopher W.
    von Mehren, Margaret
    Benjamin, Robert S.
    Raymond, A. Kevin
    Bramwell, Vivien H. C.
    Baker, Laurence H.
    Maki, Robert G.
    Tanaka, Michael
    Hecht, J. Randolph
    Heinrich, Michael C.
    Fletcher, Christopher D. M.
    Crowley, John J.
    Borden, Ernest C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) : 626 - 632